NCT04292743View on ClinicalTrials.gov

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

January 18, 2023

Study Completion Date

March 4, 2024

Conditions
Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal Adenocarcinoma
Interventions
BIOLOGICAL

Eryaspase

intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg

DRUG

FOLFIRINOX

intravenous administration of FOLFIRINOX

Trial Locations (1)

20007

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

Sponsors

Collaborators (1)

ERYtech Pharma
All Listed Sponsors
collaborator

ERYtech Pharma

INDUSTRY

lead

Georgetown University

OTHER